HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics with Buy Rating, Announces Price Target of $2.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has initiated coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and a price target of $2.5.
September 08, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics has been initiated with a Buy rating and a price target of $2.5 by HC Wainwright & Co.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $2.5 is a positive signal for ZyVersa Therapeutics. This could potentially attract more investors to the stock and drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100